Company description

Capricor Therapeutics is a clinical-stage biotechnology company that focuses on the development of regenerative and therapeutic treatments for a variety of diseases. The company uses its proprietary technology platform to discover and develop novel cellular medicines that are aimed at targeting diseases with high unmet medical needs. Capricor's pipeline includes potential treatments for Duchenne muscular dystrophy, myocardial infarction, and COVID-19. The company's lead product candidate, CAP-1002, is currently in clinical trials for Duchenne muscular dystrophy and has shown promising results in improving cardiac and skeletal muscle function. Capricor also has a partnership with the National Institutes of Health to develop treatments for COVID-19, including a potential therapy utilizing exosomes derived from CAP-1002. With a dedicated team of scientists and a strong focus on innovation, Capricor is committed to improving the lives of patients with debilitating diseases. As a publicly traded company with the ticker symbol CAPR, Capricor continues to drive research and development efforts in the field of regenerative medicine for the benefit of patients worldwide.